Oura Buys AI Primary Care Startup Counsel Health for $625M

Oura has agreed to acquire Counsel Health, an AI-native primary care startup, for $625 million, according to The Verge. The deal pairs the biometric data streams from Oura's smart rings with Counsel's AI chatbot and network of on-demand physicians, a combination the companies say is designed to let doctor visits start with a readout of a patient's own wearable data. The acquisition underscores a broader shift in healthcare AI from back-office diagnostics toward continuous, real-time patient monitoring that feeds clinical decision-making before a patient ever speaks to a doctor.

What Happened

Oura announced the acquisition alongside its quarterly earnings, confirming the $625 million price tag and stating it expects the deal to close before the end of the year, per The Verge. Counsel Health had already been integrated into the Oura app since June, letting users chat with an AI system about symptoms or lab results before escalating to one of the startup's roughly 50 in-house physicians. According to TechCrunch, the companies plan to expand that integration across three areas: preventative care, acute care for episodic concerns, and specialty or chronic care covering reproductive and cardiometabolic health.

Counsel's 70 employees, including CEO Muthu Alagappan, will join Oura as part of the deal, Alagappan will join Oura as chief clinical AI officer (remove 'newly created' descriptor, which is not supported by sources).. TechCrunch reported that Counsel raised a $25 million Series A a year ago led by Andreessen Horowitz and GV, with PitchBook estimating total funding at $36 million before the acquisition. The Counsel CEO said in the acquisition press release, as reported by TechCrunch, that Oura's data gives clinicians objective context and trended biometrics, keeping physicians in the loop for clinical decisions rather than automating care entirely.

Oura CEO Tom Hale described the logic of the deal in a press release quoted by TechCrunch, stating that the acquisition connects members' ability to understand their physiology with their ability to take action on health insights, spanning quick questions and prescriptions, lab results, chronic care management, and referrals. The Verge reported that Hale told Bloomberg the strategy is to connect wearables, clinical AI, and physician access based on insights derived from biometric data. This positions Oura to offer an end-to-end care pathway: a user's ring captures sleep, heart rate, and temperature trends; the AI chatbot analyzes those trends against reported symptoms; and a physician either handles the case or escalates it to specialty care.

The acquisition lands weeks after Oura shelved an IPO that could have raised up to $2.2 billion, with the company citing uncertainty in the IPO market, TechCrunch reported. Oura disclosed that revenue grew 153 percent year-over-year to $533 million for the quarter ended September 30, and that fiscal year 2026 revenue reached approximately $1.75 billion, up 92 percent year-over-year. The company had already reached an $11 billion valuation following a $900 million late-stage round in October 2025. TechCrunch also noted that rivals RingConn and Ultrahuman are pressing Oura's dominance in the smart ring category, adding competitive weight to the push into clinical services.

Oura stated that Counsel will continue serving existing and new enterprise partners - health plans, health systems, consumer health organizations, and employers - independent of the Oura user base, per The Verge. This dual-track strategy allows Counsel's AI platform to scale beyond Oura's hardware ecosystem while remaining within Oura's corporate structure. The Verge also reported that Alagappan is planning to expand Counsel's physician network beyond its current 50-person staff, signaling Oura's intent to scale clinical capacity alongside its growing user base.

Why It Matters

The deal extends AI's diagnostic reach beyond the radiology suite and into continuous, at-home biometric monitoring. Where the established wave of medical AI has focused on reading scans and flagging anomalies in medical imaging, Oura and Counsel are testing whether trended heart rate, sleep, and temperature data from a ring can serve a similar triage function, feeding both an AI chatbot and a human physician with objective context before a clinical conversation even starts. This approach differs from image-based AI diagnostics: rather than analyzing a static snapshot, the ring creates a longitudinal record that can reveal patterns invisible in a single encounter.

That distinction matters for a market that watches AI's clinical credibility closely. Oura shelving a $2.2 billion IPO while still spending $625 million on an acquisition signals confidence that clinical AI, not just hardware sales, is where its next growth phase sits. The company's 92 percent year-over-year revenue growth and $11 billion valuation give it financial runway to pursue a more ambitious clinical strategy than a pure-play smartwatch vendor. By acquiring a company that already employs 50 physicians and operates under healthcare regulatory frameworks, Oura is also sidestepping years of regulatory infrastructure-building that a software-only company would need to undertake. The deal positions wearable data as a first-line triage signal, a role traditionally reserved for nurse hotlines or patient portals. For investors and competitors, this acquisition tests whether continuous biometric streams can reduce unnecessary office visits or ER trips while catching genuine clinical problems earlier - outcomes that would justify both the $625 million price tag and the pivot away from a public listing into M&A-driven growth.

Background

Counsel Health emerged as an AI-native primary care company combining a chat-based medical experience with access to licensed physicians. Its $36 million in total funding before acquisition reflects investor confidence in AI-assisted primary care models, even as regulatory and reimbursement pathways remain unsettled. The startup's June integration into Oura's app represented an early proof-of-concept: users could ask the AI medical questions without leaving the Oura ecosystem, lowering friction between symptom awareness and clinical escalation.

What to Watch

Counsel's independence from the Oura user base will test whether an AI-plus-physician model scales beyond a single hardware ecosystem. If enterprise health plans and employers adopt Counsel's platform without owning Oura rings, the company's clinical credibility transcends its hardware dependency. Alagappan's expansion of the physician network beyond 50 providers will signal how aggressively Oura intends to scale clinical capacity, and whether it plans to hire, contract, or partner with medical practices. The deal's close, expected before year-end, will also reveal whether regulators flag concerns about a consumer hardware company acquiring clinical decision-making infrastructure - a regulatory question without clear precedent in the wearables space.

Further reading and context

• GPT-4 Multimodal
• AI in Healthcare — Drug Discovery, Medical Imaging, and the AlphaFold Revolution